2021 IPO
Impel NeuroPharma Stock
Medical device company developing a direct nose-to-brain delivery
Sign up today and learn more about Impel NeuroPharma Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Impel NeuroPharma Stock
Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery.
Funding History
January 2010 | $305K |
---|---|
October 2011 | $500K |
August 2012 | $25K |
November 2013 | $2.6M |
October 2015 | $0 |
August 2016 | $1.1M |
December 2016 | $36.0M |
December 2018 | $67.5M |
Management
Chief Business Officer
Richard Haiduck
Director of R&D
Alan Brunelle
Co-Founder & CEO
Michael Hite
Co-Founder & Chief Scientific Officer
John Hoekman
President & CEO
Jon Congleton